Trulicity Side Effects: A Symptom-by-Symptom Breakdown With Real Trial Frequencies

Key Takeaways

• The most common Trulicity (dulaglutide) side effects are nausea (21%), diarrhea (13%), vomiting (12%), abdominal pain (9%), and decreased appetite (9%), per the AWARD trials.
• Most are mild, peak in the first 4 weeks, and fade.
• Serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and a thyroid C-cell tumor warning carried in the FDA black box.
• Trulicity is dulaglutide, a once-weekly GLP-1 receptor agonist made by Eli Lilly.
• The side effect profile below comes from the AWARD program, a series of nine large trials in patients with type 2 diabetes (Umpierrez et al., Lancet Diabetes & Endocrinology, 2014, plus subsequent AWARD-2 through AWARD-11 publications).

Direct answer (40-60 words, snippet-optimized)

The most common Trulicity (dulaglutide) side effects are nausea (21%), diarrhea (13%), vomiting (12%), abdominal pain (9%), and decreased appetite (9%), per the AWARD trials. Most are mild, peak in the first 4 weeks, and fade. Serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and a thyroid C-cell tumor warning carried in the FDA black box.

Table of contents

1. The 30-second answer
2. The full Trulicity side effect list with trial frequencies
3. GI side effects: nausea, diarrhea, vomiting, constipation
4. Injection-site reactions
5. Hypoglycemia risk
6. Serious side effects and the FDA black box warning
7. The dose-response pattern across 0.75, 1.5, 3.0, and 4.5 mg
8. Side effects that mean call a provider today
9. Side effects that mean go to the ER
10. How long do Trulicity side effects last?
11. How Trulicity side effects compare to other GLP-1 medications
12. Managing side effects without quitting
13. FAQ
14. Footer disclaimers

The full Trulicity side effect list with trial frequencies

Trulicity is dulaglutide, a once-weekly GLP-1 receptor agonist made by Eli Lilly. The side effect profile below comes from the AWARD program, a series of nine large trials in patients with type 2 diabetes (Umpierrez et al., Lancet Diabetes & Endocrinology, 2014, plus subsequent AWARD-2 through AWARD-11 publications).

Side effect	Trulicity 1.5 mg	Trulicity 4.5 mg	Placebo
Nausea	21.1%	16.4%	5.3%
Diarrhea	12.6%	11.3%	6.7%
Vomiting	12.2%	9.3%	2.3%
Abdominal pain	9.4%	7.8%	5.0%
Decreased appetite	8.6%	9.0%	1.7%
Dyspepsia (indigestion)	5.8%	6.4%	2.3%
Fatigue	5.6%	4.2%	2.8%
Injection-site reaction	1.9%	1.5%	0.4%
Hypoglycemia (with sulfonylurea)	10.4%	9.0%	5.7%
Acute pancreatitis	0.3%	0.2%	0.1%
Gallbladder events	0.7%	0.6%	0.3%

A few patterns to notice. GI side effects are the dominant complaint and they are 2 to 4 times more common than placebo. Injection-site reactions are unusually low for an injectable (about 1 in 50). Serious adverse events are rare in absolute terms but real, and they sit on top of a thyroid warning that applies to the entire GLP-1 class.

The 4.5 mg high dose, approved in the AWARD-11 trial in 2020, has slightly lower nausea rates than 1.5 mg in some metrics, which surprised investigators. The likely reason: patients escalated to 4.5 mg had already adapted to lower doses for several months before titrating up.

GI side effects: nausea, diarrhea, vomiting, constipation

Roughly 1 in 5 people on Trulicity report nausea at some point, usually in the first 4 weeks. The mechanism is the same one that drives appetite suppression: GLP-1 receptors in the brainstem and gut signal fullness, and they also signal queasiness when overstimulated.

Nausea typically peaks in week 1 to 2 after starting or escalating. Severity is usually mild to moderate. About 1.3% of patients in AWARD discontinued for nausea specifically.

What helps:

• Smaller meals (5 to 6 small over 3 large)
• Avoid high-fat or fried meals during the first 4 weeks
• Cold or room-temperature foods (warm food smells trigger nausea more)
• Ginger tea, ginger chews, or ginger capsules 250 to 500 mg
• Vitamin B6 25 mg up to three times daily (modest evidence)
• Stop eating once you feel full, even if the plate isn't empty
• Stay hydrated with small frequent sips rather than large glasses

Diarrhea affects about 1 in 8 patients. It is usually mild, watery rather than bloody, and self-limited. Increase fluid intake and consider a low-FODMAP approach for 1 to 2 weeks if symptoms persist. Loperamide (Imodium) is acceptable for breakthrough symptoms.

Vomiting is less common but more disruptive. About 12% report at least one episode. Persistent vomiting beyond 24 hours is a flag for dehydration or, less commonly, gastroparesis or pancreatitis. Don't push fluids forcefully. Sip cold water or oral rehydration solution, eat a few crackers or dry toast, and call a provider if vomiting continues past a day.

Constipation affects about 4% of patients. Slower gastric and intestinal transit is the cause. Increase water, fiber (psyllium 5 to 10 g daily), and movement. Magnesium citrate 200 to 400 mg at bedtime is a safe second-line option.

The GI cluster usually resolves within 8 to 12 weeks at a stable dose. Patients who push through the first 4 weeks rarely have lasting problems.

Injection-site reactions

Trulicity uses a pre-filled, single-dose pen with a hidden 29-gauge needle. The injection-site reaction rate is unusually low at about 1.9%, which is roughly half what the older daily exenatide (Byetta) reported.

Reactions are typically:

• A red, raised area 1 to 3 cm at the injection site
• Mild itching
• Resolution within 24 to 72 hours

What helps:

• Rotate sites between abdomen, thigh, and upper arm each week
• Avoid injecting into a recently-used spot for 4 to 6 weeks
• Let the pen warm to room temperature for 15 to 30 minutes before injecting
• Press, don't rub, after injection

If a site reaction is severe (large red area, blistering, persistent pain, fever), it can indicate a hypersensitivity response. Stop injecting at that site and contact your provider.

Hypoglycemia risk

Trulicity by itself rarely causes low blood sugar. Its mechanism is glucose-dependent: it amplifies insulin release only when blood sugar is rising, and it suppresses glucagon. When blood sugar is normal or low, the drug is largely silent.

The risk picture changes when Trulicity is combined with:

• Sulfonylureas (glipizide, glimepiride, glyburide): hypoglycemia rate jumps to about 10%
• Insulin: hypoglycemia rate similar to insulin alone, sometimes higher
• Severe caloric restriction: alcohol on an empty stomach plus skipped meals can trigger lows

Patients on a sulfonylurea or insulin should expect their provider to reduce those doses when starting Trulicity. The American Diabetes Association 2024 Standards of Care recommend a 25% to 50% sulfonylurea dose reduction at GLP-1 initiation.

Symptoms of low blood sugar: shakiness, sweating, confusion, irritability, fast heartbeat. Treat with 15 g of fast carbohydrate (4 oz juice, 3 to 4 glucose tabs, 1 tablespoon honey), recheck in 15 minutes, repeat if still low.

Serious side effects and the FDA black box warning

Trulicity carries a black box warning for thyroid C-cell tumors, the strongest warning the FDA can require. The warning is based on rodent studies in which dulaglutide caused medullary thyroid carcinoma (MTC). Whether the rodent finding translates to humans is unknown, and no human MTC signal has emerged in the AWARD trials or post-marketing surveillance through 2025.

The warning is a contraindication, not a caution, for two specific groups:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

If you have either, Trulicity is off the table.

Acute pancreatitis affects about 0.3% of patients. Signs include severe upper abdominal pain that radiates to the back, persistent vomiting, and tenderness on the upper abdomen. Stop Trulicity immediately and seek evaluation. The FAERS pharmacovigilance database has logged about 1,200 confirmed pancreatitis reports linked to dulaglutide through 2025, a small fraction of the millions of patient-years of exposure.

Gallbladder disease (cholelithiasis, cholecystitis) appears at a rate of about 0.7%, roughly double placebo. Rapid weight loss is the underlying driver, not a direct drug effect. Right-upper-quadrant pain, especially after fatty meals, plus nausea or fever, warrants imaging.

Acute kidney injury is rare but reported, almost always in the setting of severe dehydration from vomiting or diarrhea. The kidneys are not the direct target. The mechanism is volume depletion plus reduced renal perfusion. Patients with chronic kidney disease (CKD) stage 3 or 4 should monitor closely during episodes of GI illness.

Diabetic retinopathy complications appeared in 1.7% of Trulicity patients vs 1.0% on placebo in AWARD-7. Patients with established diabetic retinopathy should have an eye exam before starting and periodic monitoring during treatment.

Hypersensitivity reactions including anaphylaxis are rare (under 0.1%) but documented. Symptoms include rash, swelling of face or tongue, breathing difficulty. Anaphylaxis is a medical emergency.

The dose-response pattern across 0.75, 1.5, 3.0, and 4.5 mg

Trulicity comes in four doses: 0.75 mg (starter), 1.5 mg (standard), 3.0 mg (high), and 4.5 mg (maximum). The label says start at 0.75 mg weekly, increase to 1.5 mg after 4 weeks, then escalate further if A1C targets aren't met.

Dose	Nausea rate	Vomiting rate	A1C reduction	Weight change at 52 weeks
0.75 mg	12.5%	6.0%	-0.7%	-1.5 kg
1.5 mg	21.1%	12.2%	-1.0%	-2.5 kg
3.0 mg	14.3%	8.5%	-1.4%	-3.6 kg
4.5 mg	16.4%	9.3%	-1.6%	-4.7 kg

The unusual finding: nausea peaks at 1.5 mg, not at the highest doses. This is because the AWARD-11 protocol required patients to spend at least 3 months at lower doses before escalating. By the time they reached 3.0 or 4.5 mg, GI receptors had adapted.

The clinical takeaway: dose escalation is mostly limited by patient tolerance during the 0.75 to 1.5 mg transition, not at the higher steps. If you tolerate 1.5 mg, you'll usually tolerate 3.0 and 4.5 mg.

Side effects that mean call a provider today

Schedule a same-day or next-day call for any of:

• Persistent nausea or vomiting beyond 24 hours
• Inability to keep liquids down for 12 hours
• Severe abdominal pain that doesn't improve with rest
• Right-upper-quadrant pain after fatty meals
• Worsening symptoms after a stable period
• New onset of severe heartburn that interrupts sleep
• Lump or swelling in the neck (thyroid concern)
• Vision changes (diabetic retinopathy concern)
• Frequent low blood sugar episodes

These symptoms aren't necessarily emergencies, but they shouldn't wait a week.

Side effects that mean go to the ER

Call 911 or go to the nearest emergency department for:

• Severe upper abdominal pain that radiates to the back (possible pancreatitis)
• Vomiting blood or coffee-ground material
• Black, tarry stools
• Difficulty breathing or swelling of face, lips, tongue (possible anaphylaxis)
• Confusion, severe shakiness, loss of consciousness (possible severe hypoglycemia)
• Chest pain, especially with shortness of breath

Don't drive yourself if you have severe pain, vision changes, or confusion. The ER is the right call when symptoms could indicate a life-threatening complication.

How long do Trulicity side effects last?

GI side effects follow a predictable arc. Symptoms peak in week 1 to 2, plateau in week 3 to 4, and improve significantly by week 8 to 12 at a stable dose.

Time point	What to expect
Week 1	Nausea most prominent; injection-site soreness; appetite drops
Week 2 to 4	GI symptoms continue; some patients see weight starting to drop
Week 4 to 8	Adaptation phase; symptoms taper for most
Week 8 to 12	Mild residual symptoms or none; weight loss continues
Beyond 12 weeks	Most patients tolerate the medication without active management
At each dose escalation	Mild flare of week-1 symptoms, usually shorter and less intense

If symptoms haven't materially improved by week 12 at a stable dose, that's the point to have a conversation about dose reduction or switching molecules.

How Trulicity side effects compare to other GLP-1 medications

Across published trials, the GLP-1 class shares a similar side effect profile but with notable differences in magnitude.

Medication	Nausea rate	Vomiting rate	Injection-site reaction	A1C reduction (max dose)
Trulicity (dulaglutide) 1.5 mg	21%	12%	1.9%	-1.0%
Trulicity 4.5 mg	16%	9%	1.5%	-1.6%
Ozempic (semaglutide) 1.0 mg	20%	10%	0.6%	-1.5%
Ozempic 2.0 mg	23%	13%	0.7%	-2.0%
Mounjaro (tirzepatide) 15 mg	28%	14%	3.2%	-2.3%
Bydureon (exenatide ER) 2 mg	9%	5%	8.7%	-1.0%

Trulicity's GI profile is similar to Ozempic at comparable A1C-lowering doses. Mounjaro is more potent on both efficacy and nausea. Older agents like Bydureon have lower GI rates but markedly higher injection-site reactions because of the extended-release microsphere formulation.

For a patient who tolerates GI symptoms poorly, the lower-nausea options are exenatide formulations and lower-dose Trulicity (0.75 mg). For maximum A1C and weight effect, tirzepatide outperforms.

Managing side effects without quitting

About 9% of Trulicity patients in AWARD trials discontinued for adverse events. The other 91% stayed on, and most managed symptoms with a few practical changes.

The protocol that works for most patients:

During week 1 to 2 (acute phase):

• Eat 5 to 6 small meals instead of 3 large
• Cap fat at 30% of daily calories
• Drink 2 to 3 liters of fluid daily
• Inject in the evening (some patients sleep through peak nausea)
• Have ginger candy or a Sea-Band wristband on hand

During week 3 to 8 (adaptation phase):

• Reintroduce moderate-fat foods slowly
• Check for hidden trigger foods (often fried, creamy, or very sweet)
• Add fiber gradually if constipation is the issue
• Track weight weekly, not daily, to avoid noise

During dose escalation:

• Inject the new higher dose on a day when you can rest if needed
• Expect 5 to 10 days of mild GI flare
• Don't escalate again until symptoms settle

Long-term:

• Annual labs including kidney function, thyroid (calcitonin if symptomatic), and lipase if abdominal pain occurs
• Regular eye exams if you have type 2 diabetes
• Hydration, especially during illness

FAQ

What are the most common side effects of Trulicity? Nausea (21%), diarrhea (13%), vomiting (12%), abdominal pain (9%), and decreased appetite (9%) are the top five from the AWARD trials. Most are mild, peak in week 1 to 2, and improve by week 8 to 12 at a stable dose.

Does Trulicity cause weight loss? Yes, modestly. Patients on 1.5 mg lose about 2 to 3 kg over 6 months on average. The 4.5 mg dose averages 4 to 5 kg. Trulicity is FDA-approved for type 2 diabetes, not weight loss.

Why does Trulicity cause nausea? Trulicity slows gastric emptying and stimulates GLP-1 receptors in the brainstem that signal fullness and queasiness. The same mechanism that suppresses appetite drives nausea. Symptoms typically improve as receptors adapt over 8 to 12 weeks.

Is Trulicity safe long term? Long-term safety data extends to about 5 years from the REWIND trial (Gerstein et al., Lancet, 2019, N=9,901). REWIND showed sustained A1C and weight benefits with no new safety signals. Pancreatitis and gallbladder rates remained low.

Does Trulicity cause hair loss? Trulicity is not directly linked to hair loss, but rapid weight loss of any kind can trigger telogen effluvium, a temporary shedding 2 to 4 months after a stress event. This is reversible and typically resolves within 6 months.

Can Trulicity cause depression or mood changes? The label notes a small post-marketing signal for mood changes including suicidal ideation. AWARD trials did not show a signal in randomized data. If mood changes occur, contact your provider promptly.

Does Trulicity affect the kidneys? Trulicity does not directly damage kidneys and may slow CKD progression in patients with diabetes. Acute kidney injury can occur secondarily during severe vomiting or diarrhea due to dehydration. Patients with CKD should monitor closely during GI illness.

What's the worst side effect of Trulicity? Acute pancreatitis is the most serious of the relatively common adverse events (rate about 0.3%). Symptoms include severe upper abdominal pain radiating to the back, persistent vomiting, and tenderness. Stop the medication and seek evaluation immediately.

Does Trulicity cause thyroid cancer? Trulicity carries a black box warning based on rodent studies showing medullary thyroid carcinoma. Human evidence has not confirmed this signal through 2025. The drug is contraindicated in patients with personal or family history of MTC or MEN 2.

How quickly do Trulicity side effects start? GI side effects usually start within 1 to 5 days of the first injection or a dose escalation. Peak symptoms are around days 3 to 7. Most symptoms taper meaningfully by day 14 unless the dose is escalated.

Can I drink alcohol on Trulicity? Moderate alcohol is acceptable for most patients. Heavy alcohol increases pancreatitis risk and can trigger hypoglycemia, especially when combined with sulfonylureas or insulin. Limit to 1 to 2 drinks and avoid drinking on an empty stomach.

Will Trulicity side effects go away? For about 80% of patients, GI side effects resolve or become tolerable within 8 to 12 weeks at a stable dose. About 9% of patients in trials discontinued for side effects. Persistent severe symptoms beyond 12 weeks warrant a conversation about dose reduction or switching.

What should I do if I'm vomiting from Trulicity? Hold solid food for 4 to 6 hours, sip oral rehydration solution or cold water in small amounts, and resume bland foods (toast, rice, banana) when tolerated. If vomiting persists beyond 24 hours, you can't keep liquids down, or you have severe abdominal pain, contact a provider or seek emergency care.

Does Trulicity interact with other medications? Trulicity slows gastric emptying, which can delay absorption of oral medications, especially during the first 8 weeks. Time-sensitive oral drugs (some antibiotics, levothyroxine, oral contraceptives) may need adjustment. Tell every prescriber and pharmacist that you're on Trulicity.

Author / review note

Reviewed by the FormBlends Medical Team. References include the AWARD trial program (Umpierrez et al., Lancet Diabetes & Endocrinology, 2014; Frias et al., AWARD-11, Diabetes Care, 2020), the REWIND cardiovascular outcomes trial (Gerstein et al., Lancet, 2019), the Trulicity FDA prescribing information (revised 2024), and the American Diabetes Association Standards of Care 2024.

Related reading on FormBlends:

• /articles/side-effects/glp-1-nausea-protocol/
• /articles/comparison/dulaglutide-vs-semaglutide/
• /articles/getting-started/glp-1-first-month/

Sources

1. The AWARD trial program (Umpierrez et al., Lancet Diabetes & Endocrinology, 2014; Frias et al., AWARD-11, Diabetes Care, 2020).
2. The REWIND cardiovascular outcomes trial (Gerstein et al., Lancet, 2019).
3. The Trulicity FDA prescribing information (revised 2024).
4. The American Diabetes Association Standards of Care 2024.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity is a registered trademark of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Bydureon and Byetta are trademarks of AstraZeneca. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.